Close menu

April 19th, 2023 | 11:20 CEST

BioNxt Solutions, Bayer, Morphosys - Using high-speed technology to beat cancer in men

  • Biotechnology
  • Pharma
  • Cancer
Photo credits: Bayer Healthcare

Cancer drugs dominate the global pharmaceutical market and register a significant share. While the global market was worth around EUR 128.6 billion in 2019, it is expected to be around EUR 159.3 billion in 2022. This is reason enough for pharmaceutical companies such as Bayer and Morphosys to advance their research in these areas. Men are particularly affected by specific types of cancer. But what good is the best therapeutic agent if the effect is not achieved immediately? This is precisely where BioNxt Solutions comes in, with a unique coating technology for the rapid release of active substances.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: Bionxt Solutions Inc. | CA0909741062 , BAYER AG NA O.N. | DE000BAY0017 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:

    Sébastien Plouffe, CEO and Director, Defence Therapeutics
    "[...] Accum™ helps us target active ingredients precisely to the origin of infections or diseases. [...]" Sébastien Plouffe, CEO and Director, Defence Therapeutics

    Full interview


    BioNxt Solutions - Novel coating ensures rapid release of active ingredient

    Anyone who has ever been unwell knows that moment when, after taking a medicine, the effect unfolds in the body, and the active ingredient does its work.

    **This is where BioNxt comes in, with a novel coating technology for orally administered drugs and active ingredients. The faster the active ingredient of an orally administered drug unfolds its effect, the faster patients feel relief from their symptoms. A so-called coating technology is responsible for the commercial implementation. Particularly exciting for investors: this technology can be patented.

    "With BioNxt already having established platforms for transdermal and oral soluble drug delivery, this acquisition of a novel coating technology for oral drugs is a significant step in expanding and consolidating our drug delivery expertise," said Hugh Rogers, CEO & Director of BioNxt.

    The logic behind this is understandable: the faster a drug provides relief, the higher the repeat purchase or prescription. That is because the increased speed of symptom relief allows patients to return to their usual quality of life sooner.

    BioNxt is dedicated to helping patients regain their quality of life. Its solutions at the point of care offer rapid diagnosis, associated rapid relief and gentle drug delivery. BioNxt sees itself as an accelerator, and its successes to date prove it right: the faster patients experience relief, the greater the appreciation of the successes BioNxt provides through its research and work.

    Bayer - New results in the fight against prostate cancer

    In recent decades, the number of new cases of prostate cancer within the group of adult men has increased worldwide. In Europe, approximately 2.6 million new cases are diagnosed each year.

    Signs of prostate cancer include difficulty urinating, blood in the urine or seminal fluid, pain during ejaculation and in the back, pelvis or hips, and potency problems. These warning signs should be clarified immediately by a doctor so that a possible serious illness can be recognised and treated at an early stage.

    Bayer is strongly committed to advancing oncology research and development, focusing on three scientific areas that have the potential to address the unmet needs of cancer patients.

    These include:

    1. next generation immuno-oncology
    2. targeted radionuclide therapies
    3. molecular precision oncology

    Important data from all three areas will be presented at this year's conference to demonstrate Bayer's progress and achievements in oncology research. Precision oncology will be presented, underscoring Bayer's commitment to advancing the future of cancer treatment.

    Bayer is committed to researching its prostate cancer drug, darolutamide, to help many men affected by the disease. Bayer remains committed to advancing the research and development of darolutamide and other innovative drugs to fight prostate cancer.

    Morphosys - Achieves first results in the fight against bone marrow cancer

    Myelofibrosis is a malignant and rare disease of the bone marrow that occurs in the form of primary myelofibrosis (PMF) or as a secondary consequence of another myeloproliferative disease. In Germany, about 0.5 to 1.5 out of 100,000 people develop this type of cancer every year. That corresponds to approximately 1,000 new cases per year, with the average age of those affected being around 65 years.

    Men are affected slightly more often than women, accounting for 65% of cases. Although myelofibrosis is not inherited according to current knowledge, there are familial clusters. Morphosys AG completed enrolment in the study investigating its therapeutic in the fight against this insidious disease at the beginning of April. This is a Phase III study investigating the efficacy and safety of pelabresib, a BET inhibitor, in combination with ruxolitinib in patients with myelofibrosis who have not previously been treated with a JAK inhibitor.

    Combination therapy is being studied in comparison to ruxolitinib alone. Top-line data will be published earlier than expected in late 2023, which is positive for the stock. Incyte (INCY) is currently in trials of its own BET inhibitor, which can be used in combination with Jakafi. The product is undergoing Phase I trials and being tested for efficacy. In addition, the Company has another product in Phase III, the PI3K inhibitor parsaclisib. This is being studied as a combination therapy with ruxolitinib in patients who do not respond adequately to ruxolitinib. Results are due to be published in 2023. However, class-wide safety overhang is a major problem, as has already been observed with Incyte. The Company had to withdraw the NDA for marginal zone lymphoma, follicular lymphoma and mantle cell lymphoma.

    For patients who have already been diagnosed, speed is everything. That is where BioNxt Solutions comes in, with its novel coating technology that enables conventional agents to relieve disease symptoms more quickly. For pharma and doctors, this is one of the main arguments for helping sufferers. Anyone who has ever taken a drug in the hope that it would work quickly - and it didn't - appreciates the speed of drug release. On the other hand, more and more men should take a closer look at the shares of Bayer. The increase in prostate cancer seems concerning. It is all the more valuable that a company like Bayer is focusing on where a man's most precious asset is permanently at risk, and non-treatment could end fatally. Morphosys is also joining the fight against cancer, in this case, bone marrow cancer. Here, men are also more often affected than women. Investors should carefully consider who they are backing with their investment.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.


    Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST

    JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

    • Mining
    • phosphate
    • photovoltaics
    • Biotechnology

    The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?


    Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST

    Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!

    • Biotechnology
    • Pharma
    • vaccine

    Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.